The global Human High-density Lipoprotein Particles market was valued at US$ 106 million in 2025 and is anticipated to reach US$ 233 million by 2032, at a CAGR of 12.0% from 2026 to 2032.

Human High-density Lipoprotein Particles Market

Human high-density lipoprotein (HDL) particles are a type of natural lipoprotein complex derived from human plasma. They typically have apolipoprotein A-I (ApoA-I) as their core framework, with an outer layer composed of phospholipids and free cholesterol, and an interior rich in cholesterol esters and accompanied by small amounts of triglycerides. These particles primarily function as reverse cholesterol transporters in the body, transporting excess cholesterol from peripheral tissues and blood vessel walls back to the liver for metabolism and clearance. They also possess anti-inflammatory, antioxidant, and endothelial protective biological activities. Due to their preservation of natural conformation and functional properties, human HDL particles are widely used in basic and translational medical research related to cardiovascular diseases, lipid metabolism, inflammatory responses, and drug mechanisms. In 2025, sales volume was 356,000 units, with an average price of $300, total production capacity of 400,000 units, and a gross profit margin of 82%.

The North American market for Human High-density Lipoprotein Particles is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for Human High-density Lipoprotein Particles is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The global market for Human High-density Lipoprotein Particles in Biological Laboratories is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.

Major global companies of Human High-density Lipoprotein Particles include Novartis, Amgen, Betta Pharmaceuticals, Thermo Fisher Scientific Inc., Eli Lilly and Company, Bio-Techne, Merck, Yeasen, Sino Biological, Miltenyi Biotec, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global Human High-density Lipoprotein Particles market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Human High-density Lipoprotein Particles. The Human High-density Lipoprotein Particles market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Human High-density Lipoprotein Particles market comprehensively. Regional market sizes by Type, by Application, by Functional State, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Human High-density Lipoprotein Particles manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Human High-density Lipoprotein Particles Market Report

Report Metric	Details
Report Name	Human High-density Lipoprotein Particles Market
Accounted market size in 2025	US$ 106 million
Forecasted market size in 2032	US$ 233 million
CAGR	12.0%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Purity＞95% Purity≤95%
Segment by Functional State	HDL₂ HDL₃
Segment by Apolipoprotein Composition	ApoA-I-containing HDL ApoA-I/ApoA-II HDL
Segment by Application	Biological Laboratories University Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novartis, Amgen, Betta Pharmaceuticals, Thermo Fisher Scientific Inc., Eli Lilly and Company, Bio-Techne, Merck, Yeasen, Sino Biological, Miltenyi Biotec, Proteintech, BioLegend
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Functional State, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Human High-density Lipoprotein Particles companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Human High-density Lipoprotein Particles Market growing?

Ans: The Human High-density Lipoprotein Particles Market witnessing a CAGR of 12.0% during the forecast period 2026-2032.

What is the Human High-density Lipoprotein Particles Market size in 2032?

Ans: The Human High-density Lipoprotein Particles Market size in 2032 will be US$ 233 million.

Who are the main players in the Human High-density Lipoprotein Particles Market report?

Ans: The main players in the Human High-density Lipoprotein Particles Market are Novartis, Amgen, Betta Pharmaceuticals, Thermo Fisher Scientific Inc., Eli Lilly and Company, Bio-Techne, Merck, Yeasen, Sino Biological, Miltenyi Biotec, Proteintech, BioLegend

What are the Application segmentation covered in the Human High-density Lipoprotein Particles Market report?

Ans: The Applications covered in the Human High-density Lipoprotein Particles Market report are Biological Laboratories, University, Others

What are the Type segmentation covered in the Human High-density Lipoprotein Particles Market report?

Ans: The Types covered in the Human High-density Lipoprotein Particles Market report are Purity＞95%, Purity≤95%

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Human High-density Lipoprotein Particles Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Purity＞95%

1.2.3 Purity≤95%

1.3 Market by Functional State

1.3.1 Global Human High-density Lipoprotein Particles Market Size Growth Rate by Functional State: 2021 vs 2025 vs 2032

1.3.2 HDL₂

1.3.3 HDL₃

1.4 Market by Apolipoprotein Composition

1.4.1 Global Human High-density Lipoprotein Particles Market Size Growth Rate by Apolipoprotein Composition: 2021 vs 2025 vs 2032

1.4.2 ApoA-I-containing HDL

1.4.3 ApoA-I/ApoA-II HDL

1.5 Market by Application

1.5.1 Global Human High-density Lipoprotein Particles Market Growth by Application: 2021 vs 2025 vs 2032

1.5.2 Biological Laboratories

1.5.3 University

1.5.4 Others

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Global Growth Trends

2.1 Global Human High-density Lipoprotein Particles Market Perspective (2021–2032)

2.2 Global Human High-density Lipoprotein Particles Growth Trends by Region

2.2.1 Global Human High-density Lipoprotein Particles Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Human High-density Lipoprotein Particles Historic Market Size by Region (2021–2026)

2.2.3 Human High-density Lipoprotein Particles Forecasted Market Size by Region (2027–2032)

2.3 Human High-density Lipoprotein Particles Market Dynamics

2.3.1 Human High-density Lipoprotein Particles Industry Trends

2.3.2 Human High-density Lipoprotein Particles Market Drivers

2.3.3 Human High-density Lipoprotein Particles Market Challenges

2.3.4 Human High-density Lipoprotein Particles Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Human High-density Lipoprotein Particles Players by Revenue

3.1.1 Global Top Human High-density Lipoprotein Particles Players by Revenue (2021–2026)

3.1.2 Global Human High-density Lipoprotein Particles Revenue Market Share by Players (2021–2026)

3.2 Global Top Human High-density Lipoprotein Particles Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Human High-density Lipoprotein Particles Revenue

3.4 Global Human High-density Lipoprotein Particles Market Concentration Ratio

3.4.1 Global Human High-density Lipoprotein Particles Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Human High-density Lipoprotein Particles Revenue in 2025

3.5 Global Key Players of Human High-density Lipoprotein Particles Head Offices and Areas Served

3.6 Global Key Players of Human High-density Lipoprotein Particles, Products and Applications

3.7 Global Key Players of Human High-density Lipoprotein Particles, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Human High-density Lipoprotein Particles Breakdown Data by Type

4.1 Global Human High-density Lipoprotein Particles Historic Market Size by Type (2021–2026)

4.2 Global Human High-density Lipoprotein Particles Forecasted Market Size by Type (2027–2032)

5 Human High-density Lipoprotein Particles Breakdown Data by Application

5.1 Global Human High-density Lipoprotein Particles Historic Market Size by Application (2021–2026)

5.2 Global Human High-density Lipoprotein Particles Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Human High-density Lipoprotein Particles Market Size (2021–2032)

6.2 North America Human High-density Lipoprotein Particles Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Human High-density Lipoprotein Particles Market Size by Country (2021–2026)

6.4 North America Human High-density Lipoprotein Particles Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Human High-density Lipoprotein Particles Market Size (2021–2032)

7.2 Europe Human High-density Lipoprotein Particles Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Human High-density Lipoprotein Particles Market Size by Country (2021–2026)

7.4 Europe Human High-density Lipoprotein Particles Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Human High-density Lipoprotein Particles Market Size (2021–2032)

8.2 Asia-Pacific Human High-density Lipoprotein Particles Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Human High-density Lipoprotein Particles Market Size by Region (2021–2026)

8.4 Asia-Pacific Human High-density Lipoprotein Particles Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Human High-density Lipoprotein Particles Market Size (2021–2032)

9.2 Latin America Human High-density Lipoprotein Particles Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Human High-density Lipoprotein Particles Market Size by Country (2021–2026)

9.4 Latin America Human High-density Lipoprotein Particles Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Human High-density Lipoprotein Particles Market Size (2021–2032)

10.2 Middle East & Africa Human High-density Lipoprotein Particles Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Human High-density Lipoprotein Particles Market Size by Country (2021–2026)

10.4 Middle East & Africa Human High-density Lipoprotein Particles Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Novartis

11.1.1 Novartis Company Details

11.1.2 Novartis Business Overview

11.1.3 Novartis Human High-density Lipoprotein Particles Introduction

11.1.4 Novartis Revenue in Human High-density Lipoprotein Particles Business (2021–2026)

11.1.5 Novartis Recent Development

11.2 Amgen

11.2.1 Amgen Company Details

11.2.2 Amgen Business Overview

11.2.3 Amgen Human High-density Lipoprotein Particles Introduction

11.2.4 Amgen Revenue in Human High-density Lipoprotein Particles Business (2021–2026)

11.2.5 Amgen Recent Development

11.3 Betta Pharmaceuticals

11.3.1 Betta Pharmaceuticals Company Details

11.3.2 Betta Pharmaceuticals Business Overview

11.3.3 Betta Pharmaceuticals Human High-density Lipoprotein Particles Introduction

11.3.4 Betta Pharmaceuticals Revenue in Human High-density Lipoprotein Particles Business (2021–2026)

11.3.5 Betta Pharmaceuticals Recent Development

11.4 Thermo Fisher Scientific Inc.

11.4.1 Thermo Fisher Scientific Inc. Company Details

11.4.2 Thermo Fisher Scientific Inc. Business Overview

11.4.3 Thermo Fisher Scientific Inc. Human High-density Lipoprotein Particles Introduction

11.4.4 Thermo Fisher Scientific Inc. Revenue in Human High-density Lipoprotein Particles Business (2021–2026)

11.4.5 Thermo Fisher Scientific Inc. Recent Development

11.5 Eli Lilly and Company

11.5.1 Eli Lilly and Company Company Details

11.5.2 Eli Lilly and Company Business Overview

11.5.3 Eli Lilly and Company Human High-density Lipoprotein Particles Introduction

11.5.4 Eli Lilly and Company Revenue in Human High-density Lipoprotein Particles Business (2021–2026)

11.5.5 Eli Lilly and Company Recent Development

11.6 Bio-Techne

11.6.1 Bio-Techne Company Details

11.6.2 Bio-Techne Business Overview

11.6.3 Bio-Techne Human High-density Lipoprotein Particles Introduction

11.6.4 Bio-Techne Revenue in Human High-density Lipoprotein Particles Business (2021–2026)

11.6.5 Bio-Techne Recent Development

11.7 Merck

11.7.1 Merck Company Details

11.7.2 Merck Business Overview

11.7.3 Merck Human High-density Lipoprotein Particles Introduction

11.7.4 Merck Revenue in Human High-density Lipoprotein Particles Business (2021–2026)

11.7.5 Merck Recent Development

11.8 Yeasen

11.8.1 Yeasen Company Details

11.8.2 Yeasen Business Overview

11.8.3 Yeasen Human High-density Lipoprotein Particles Introduction

11.8.4 Yeasen Revenue in Human High-density Lipoprotein Particles Business (2021–2026)

11.8.5 Yeasen Recent Development

11.9 Sino Biological

11.9.1 Sino Biological Company Details

11.9.2 Sino Biological Business Overview

11.9.3 Sino Biological Human High-density Lipoprotein Particles Introduction

11.9.4 Sino Biological Revenue in Human High-density Lipoprotein Particles Business (2021–2026)

11.9.5 Sino Biological Recent Development

11.10 Miltenyi Biotec

11.10.1 Miltenyi Biotec Company Details

11.10.2 Miltenyi Biotec Business Overview

11.10.3 Miltenyi Biotec Human High-density Lipoprotein Particles Introduction

11.10.4 Miltenyi Biotec Revenue in Human High-density Lipoprotein Particles Business (2021–2026)

11.10.5 Miltenyi Biotec Recent Development

11.11 Proteintech

11.11.1 Proteintech Company Details

11.11.2 Proteintech Business Overview

11.11.3 Proteintech Human High-density Lipoprotein Particles Introduction

11.11.4 Proteintech Revenue in Human High-density Lipoprotein Particles Business (2021–2026)

11.11.5 Proteintech Recent Development

11.12 BioLegend

11.12.1 BioLegend Company Details

11.12.2 BioLegend Business Overview

11.12.3 BioLegend Human High-density Lipoprotein Particles Introduction

11.12.4 BioLegend Revenue in Human High-density Lipoprotein Particles Business (2021–2026)

11.12.5 BioLegend Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Novartis

Amgen Inc

Betta Pharmaceuticals

Thermo Fisher Scientific Inc

Eli Lilly and Company

List of Tables

Table 1. Global Human High-density Lipoprotein Particles Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Purity＞95%

Table 3. Key Players of Purity≤95%

Table 4. Global Human High-density Lipoprotein Particles Market Size Growth Rate by Functional State (US$ Million): 2021 vs 2025 vs 2032

Table 5. Key Players of HDL₂

Table 6. Key Players of HDL₃

Table 7. Global Human High-density Lipoprotein Particles Market Size Growth Rate by Apolipoprotein Composition (US$ Million): 2021 vs 2025 vs 2032

Table 8. Key Players of ApoA-I-containing HDL

Table 9. Key Players of ApoA-I/ApoA-II HDL

Table 10. Global Human High-density Lipoprotein Particles Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 11. Global Human High-density Lipoprotein Particles Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 12. Global Human High-density Lipoprotein Particles Market Size by Region (US$ Million), 2021–2026

Table 13. Global Human High-density Lipoprotein Particles Market Share by Region (2021–2026)

Table 14. Global Human High-density Lipoprotein Particles Forecasted Market Size by Region (US$ Million), 2027–2032

Table 15. Global Human High-density Lipoprotein Particles Market Share by Region (2027–2032)

Table 16. Human High-density Lipoprotein Particles Market Trends

Table 17. Human High-density Lipoprotein Particles Market Drivers

Table 18. Human High-density Lipoprotein Particles Market Challenges

Table 19. Human High-density Lipoprotein Particles Market Restraints

Table 20. Global Human High-density Lipoprotein Particles Revenue by Players (US$ Million), 2021–2026

Table 21. Global Human High-density Lipoprotein Particles Market Share by Players (2021–2026)

Table 22. Global Top Human High-density Lipoprotein Particles Players by Tier (Tier 1, Tier 2, and Tier 3), based on Human High-density Lipoprotein Particles Revenue, 2025

Table 23. Ranking of Global Top Human High-density Lipoprotein Particles Companies by Revenue (US$ Million) in 2025

Table 24. Global 5 Largest Players Market Share by Human High-density Lipoprotein Particles Revenue (CR5 and HHI), 2021–2026

Table 25. Global Key Players of Human High-density Lipoprotein Particles, Headquarters and Area Served

Table 26. Global Key Players of Human High-density Lipoprotein Particles, Products and Applications

Table 27. Global Key Players of Human High-density Lipoprotein Particles, Date of General Availability (GA)

Table 28. Mergers and Acquisitions, Expansion Plans

Table 29. Global Human High-density Lipoprotein Particles Market Size by Type (US$ Million), 2021–2026

Table 30. Global Human High-density Lipoprotein Particles Revenue Market Share by Type (2021–2026)

Table 31. Global Human High-density Lipoprotein Particles Forecasted Market Size by Type (US$ Million), 2027–2032

Table 32. Global Human High-density Lipoprotein Particles Revenue Market Share by Type (2027–2032)

Table 33. Global Human High-density Lipoprotein Particles Market Size by Application (US$ Million), 2021–2026

Table 34. Global Human High-density Lipoprotein Particles Revenue Market Share by Application (2021–2026)

Table 35. Global Human High-density Lipoprotein Particles Forecasted Market Size by Application (US$ Million), 2027–2032

Table 36. Global Human High-density Lipoprotein Particles Revenue Market Share by Application (2027–2032)

Table 37. North America Human High-density Lipoprotein Particles Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 38. North America Human High-density Lipoprotein Particles Market Size by Country (US$ Million), 2021–2026

Table 39. North America Human High-density Lipoprotein Particles Market Size by Country (US$ Million), 2027–2032

Table 40. Europe Human High-density Lipoprotein Particles Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 41. Europe Human High-density Lipoprotein Particles Market Size by Country (US$ Million), 2021–2026

Table 42. Europe Human High-density Lipoprotein Particles Market Size by Country (US$ Million), 2027–2032

Table 43. Asia-Pacific Human High-density Lipoprotein Particles Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 44. Asia-Pacific Human High-density Lipoprotein Particles Market Size by Region (US$ Million), 2021–2026

Table 45. Asia-Pacific Human High-density Lipoprotein Particles Market Size by Region (US$ Million), 2027–2032

Table 46. Latin America Human High-density Lipoprotein Particles Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 47. Latin America Human High-density Lipoprotein Particles Market Size by Country (US$ Million), 2021–2026

Table 48. Latin America Human High-density Lipoprotein Particles Market Size by Country (US$ Million), 2027–2032

Table 49. Middle East & Africa Human High-density Lipoprotein Particles Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 50. Middle East & Africa Human High-density Lipoprotein Particles Market Size by Country (US$ Million), 2021–2026

Table 51. Middle East & Africa Human High-density Lipoprotein Particles Market Size by Country (US$ Million), 2027–2032

Table 52. Novartis Company Details

Table 53. Novartis Business Overview

Table 54. Novartis Human High-density Lipoprotein Particles Product

Table 55. Novartis Revenue in Human High-density Lipoprotein Particles Business (US$ Million), 2021–2026

Table 56. Novartis Recent Development

Table 57. Amgen Company Details

Table 58. Amgen Business Overview

Table 59. Amgen Human High-density Lipoprotein Particles Product

Table 60. Amgen Revenue in Human High-density Lipoprotein Particles Business (US$ Million), 2021–2026

Table 61. Amgen Recent Development

Table 62. Betta Pharmaceuticals Company Details

Table 63. Betta Pharmaceuticals Business Overview

Table 64. Betta Pharmaceuticals Human High-density Lipoprotein Particles Product

Table 65. Betta Pharmaceuticals Revenue in Human High-density Lipoprotein Particles Business (US$ Million), 2021–2026

Table 66. Betta Pharmaceuticals Recent Development

Table 67. Thermo Fisher Scientific Inc. Company Details

Table 68. Thermo Fisher Scientific Inc. Business Overview

Table 69. Thermo Fisher Scientific Inc. Human High-density Lipoprotein Particles Product

Table 70. Thermo Fisher Scientific Inc. Revenue in Human High-density Lipoprotein Particles Business (US$ Million), 2021–2026

Table 71. Thermo Fisher Scientific Inc. Recent Development

Table 72. Eli Lilly and Company Company Details

Table 73. Eli Lilly and Company Business Overview

Table 74. Eli Lilly and Company Human High-density Lipoprotein Particles Product

Table 75. Eli Lilly and Company Revenue in Human High-density Lipoprotein Particles Business (US$ Million), 2021–2026

Table 76. Eli Lilly and Company Recent Development

Table 77. Bio-Techne Company Details

Table 78. Bio-Techne Business Overview

Table 79. Bio-Techne Human High-density Lipoprotein Particles Product

Table 80. Bio-Techne Revenue in Human High-density Lipoprotein Particles Business (US$ Million), 2021–2026

Table 81. Bio-Techne Recent Development

Table 82. Merck Company Details

Table 83. Merck Business Overview

Table 84. Merck Human High-density Lipoprotein Particles Product

Table 85. Merck Revenue in Human High-density Lipoprotein Particles Business (US$ Million), 2021–2026

Table 86. Merck Recent Development

Table 87. Yeasen Company Details

Table 88. Yeasen Business Overview

Table 89. Yeasen Human High-density Lipoprotein Particles Product

Table 90. Yeasen Revenue in Human High-density Lipoprotein Particles Business (US$ Million), 2021–2026

Table 91. Yeasen Recent Development

Table 92. Sino Biological Company Details

Table 93. Sino Biological Business Overview

Table 94. Sino Biological Human High-density Lipoprotein Particles Product

Table 95. Sino Biological Revenue in Human High-density Lipoprotein Particles Business (US$ Million), 2021–2026

Table 96. Sino Biological Recent Development

Table 97. Miltenyi Biotec Company Details

Table 98. Miltenyi Biotec Business Overview

Table 99. Miltenyi Biotec Human High-density Lipoprotein Particles Product

Table 100. Miltenyi Biotec Revenue in Human High-density Lipoprotein Particles Business (US$ Million), 2021–2026

Table 101. Miltenyi Biotec Recent Development

Table 102. Proteintech Company Details

Table 103. Proteintech Business Overview

Table 104. Proteintech Human High-density Lipoprotein Particles Product

Table 105. Proteintech Revenue in Human High-density Lipoprotein Particles Business (US$ Million), 2021–2026

Table 106. Proteintech Recent Development

Table 107. BioLegend Company Details

Table 108. BioLegend Business Overview

Table 109. BioLegend Human High-density Lipoprotein Particles Product

Table 110. BioLegend Revenue in Human High-density Lipoprotein Particles Business (US$ Million), 2021–2026

Table 111. BioLegend Recent Development

Table 112. Research Programs/Design for This Report

Table 113. Key Data Information from Secondary Sources

Table 114. Key Data Information from Primary Sources

Table 115. Authors List of This Report

List of Figures

Figure 1. Human High-density Lipoprotein Particles Picture

Figure 2. Global Human High-density Lipoprotein Particles Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Human High-density Lipoprotein Particles Market Share by Type: 2025 vs 2032

Figure 4. Purity＞95% Features

Figure 5. Purity≤95% Features

Figure 6. Global Human High-density Lipoprotein Particles Market Size Comparison by Functional State (US$ Million), 2021–2032

Figure 7. HDL₂ Features

Figure 8. HDL₃ Features

Figure 9. Global Human High-density Lipoprotein Particles Market Size Comparison by Apolipoprotein Composition (US$ Million), 2021–2032

Figure 10. ApoA-I-containing HDL Features

Figure 11. ApoA-I/ApoA-II HDL Features

Figure 12. Global Human High-density Lipoprotein Particles Market Size by Application (US$ Million), 2021–2032

Figure 13. Global Human High-density Lipoprotein Particles Market Share by Application: 2025 vs 2032

Figure 14. Biological Laboratories Case Studies

Figure 15. University Case Studies

Figure 16. Others Case Studies

Figure 17. Human High-density Lipoprotein Particles Report Years Considered

Figure 18. Global Human High-density Lipoprotein Particles Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 19. Global Human High-density Lipoprotein Particles Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 20. Global Human High-density Lipoprotein Particles Market Share by Region: 2025 vs 2032

Figure 21. Global Human High-density Lipoprotein Particles Market Share by Players in 2025

Figure 22. Global Human High-density Lipoprotein Particles Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 23. The Top 10 and 5 Players Market Share by Human High-density Lipoprotein Particles Revenue in 2025

Figure 24. North America Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 25. North America Human High-density Lipoprotein Particles Market Share by Country (2021–2032)

Figure 26. United States Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. Canada Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. Europe Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Europe Human High-density Lipoprotein Particles Market Share by Country (2021–2032)

Figure 30. Germany Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. France Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. U.K. Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Italy Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Russia Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Ireland Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. Asia-Pacific Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Asia-Pacific Human High-density Lipoprotein Particles Market Share by Region (2021–2032)

Figure 38. China Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Japan Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. South Korea Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Southeast Asia Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. India Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Australia & New Zealand Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Latin America Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Latin America Human High-density Lipoprotein Particles Market Share by Country (2021–2032)

Figure 46. Mexico Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Brazil Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. Middle East & Africa Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Middle East & Africa Human High-density Lipoprotein Particles Market Share by Country (2021–2032)

Figure 50. Israel Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 51. Saudi Arabia Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 52. UAE Human High-density Lipoprotein Particles Market Size YoY Growth (US$ Million), 2021–2032

Figure 53. Novartis Revenue Growth Rate in Human High-density Lipoprotein Particles Business (2021–2026)

Figure 54. Amgen Revenue Growth Rate in Human High-density Lipoprotein Particles Business (2021–2026)

Figure 55. Betta Pharmaceuticals Revenue Growth Rate in Human High-density Lipoprotein Particles Business (2021–2026)

Figure 56. Thermo Fisher Scientific Inc. Revenue Growth Rate in Human High-density Lipoprotein Particles Business (2021–2026)

Figure 57. Eli Lilly and Company Revenue Growth Rate in Human High-density Lipoprotein Particles Business (2021–2026)

Figure 58. Bio-Techne Revenue Growth Rate in Human High-density Lipoprotein Particles Business (2021–2026)

Figure 59. Merck Revenue Growth Rate in Human High-density Lipoprotein Particles Business (2021–2026)

Figure 60. Yeasen Revenue Growth Rate in Human High-density Lipoprotein Particles Business (2021–2026)

Figure 61. Sino Biological Revenue Growth Rate in Human High-density Lipoprotein Particles Business (2021–2026)

Figure 62. Miltenyi Biotec Revenue Growth Rate in Human High-density Lipoprotein Particles Business (2021–2026)

Figure 63. Proteintech Revenue Growth Rate in Human High-density Lipoprotein Particles Business (2021–2026)

Figure 64. BioLegend Revenue Growth Rate in Human High-density Lipoprotein Particles Business (2021–2026)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions